(NASDAQ: APVO) Aptevo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.92%.
Aptevo Therapeutics's earnings in 2026 is -$27,538,000.On average, 3 Wall Street analysts forecast APVO's earnings for 2026 to be -$25,300,496, with the lowest APVO earnings forecast at -$24,308,320, and the highest APVO earnings forecast at -$26,044,628. On average, 3 Wall Street analysts forecast APVO's earnings for 2027 to be -$22,479,955, with the lowest APVO earnings forecast at -$21,598,388, and the highest APVO earnings forecast at -$23,141,130.
In 2028, APVO is forecast to generate -$21,744,685 in earnings, with the lowest earnings forecast at -$20,891,953 and the highest earnings forecast at -$22,384,235.